Fig. 6: TGFBI orchestrates macrophages through enhancing PDGF-B expression.

A Western blot analyses of PDGF-B in BMDM or RAW264.7 treated with rTGFBI (ng/mL) with the indicated concentrations (n = 3 independent experiments). B RT-qPCR analyses of PDGF-B in BMDM or RAW264.7 treated with rTGFBI (ng/mL) with the indicated concentrations (n = 3 independent experiments). C Western blot analysis of the indicated proteins in BMDM or RAW264.7 treated with or without rTGFBI (200 ng/mL) for 6 h. D RT-qPCR analysis of Pdgfb in BMDM or RAW264.7 treated with rTGFBI (200 ng/mL) alone or in combination with integrin αvβ3 or αvβ5 neutralizing antibody (n = 3 independent experiments). E Flow cytometry analysis and statistical analysis of the percentage of Trem2⁺CD9⁺ subpopulation in BMDM or RAW264.7 transfected with the indicated siRNAs for 24 h and treated with or without rTGFBI (200 ng/mL) for 24 h (n = 3 independent experiments). F RT-qPCR and Western blot analysis of α-SMA in HSCs cocultured with BMDMs transfected the indicated siRNAs for 24 h and treated with or without rTGFBI (200 ng/mL) for 24 h (n = 3 independent experiments). G RT-qPCR and Western blot analyses of α-SMA in HSCs treated with rTGFBI or in combination with SU11248 (n = 3 independent experiments). Mice samples (n = 4–6 per group). Data were presented as the mean ± SDs; scale bars, 50 µm; *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001; ns not significant (Student’s t test).